ANKRD13D

Across TCGA pan-cancer cohorts, ANKRD13D Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANKRD13D data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ANKRD13D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD13D expression acts as an unfavorable survival marker.

STAD, SKCM, and LIHC are the cancer types where ANKRD13D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.667	<.001	24	view →
SKCM	OS	Median	III,IV	0.111	0.802	<.001	9	view →
LIHC	OS	Median	II,III,IV	0.185	0.617	.021	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ANKRD13D–STAD (OS)

Open the STAD breakdown →